Education
About Us
Working with TipRanks
Follow Us
Restart Life Sciences (TSE:HEAL)
:HEAL
Total Valuation
Restart Life Sciences has a market cap or net worth of C$4.02M. The enterprise value is C$828.16K.
Market CapC$4.02M
Enterprise ValueC$828.16K
Share Statistics
Restart Life Sciences has 36,550,354 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding36,550,354
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Restart Life Sciences’s return on equity (ROE) is -0.75 and return on invested capital (ROIC) is 300.42%.
Return on Equity (ROE)-0.75
Return on Assets (ROA)1.18
Return on Invested Capital (ROIC)300.42%
Return on Capital Employed (ROCE)2.20
Revenue Per Employee―
Profits Per Employee10.00T>
Employee Count―
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Restart Life Sciences is ―. Restart Life Sciences’s PEG ratio is -0.02.
PE Ratio―
PS Ratio0.00
PB Ratio-3.07
Price to Fair Value-3.07
Price to FCF-12.78
Price to Operating Cash Flow-5.12
PEG Ratio-0.02
Income Statement
In the last 12 months, Restart Life Sciences had revenue of 0.00 and earned 224.75K in profits. Earnings per share was 0.01.
Revenue0.00
Gross Profit0.00
Operating Income-658.51K
Pretax Income224.75K
Net Income224.75K
EBITDA-656.20K
Earnings Per Share (EPS)0.01
Cash Flow
In the last 12 months, operating cash flow was -328.58K and capital expenditures 0.00, giving a free cash flow of -328.58K billion.
Operating Cash Flow-328.58K
Free Cash Flow-328.58K
Free Cash Flow per Share>-0.01
Dividends & Yields
Restart Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.04
52-Week Price Change57.14%
50-Day Moving Average0.10
200-Day Moving Average0.08
Relative Strength Index (RSI)54.75
Average Volume (3m)3.65K
Important Dates
Restart Life Sciences upcoming earnings date is Apr 23, 2026, TBA (Confirmed).
Last Earnings DateNov 26, 2025
Next Earnings DateApr 23, 2026
Ex-Dividend Date―
Financial Position
Restart Life Sciences as a current ratio of 0.37, with Debt / Equity ratio of 0.00%
Current Ratio0.37
Quick Ratio0.37
Debt to Market Cap0.09
Net Debt to EBITDA-0.10
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Restart Life Sciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Restart Life Sciences EV to EBITDA ratio is -1.50, with an EV/FCF ratio of -13.73.
EV to Sales0.00
EV to EBITDA-1.50
EV to Free Cash Flow-13.73
EV to Operating Cash Flow-13.73
Balance Sheet
Restart Life Sciences has C$262.38K in cash and marketable securities with C$0.00 in debt, giving a net cash position of C$262.38K billion.
Cash & Marketable SecuritiesC$262.38K
Total DebtC$0.00
Net CashC$262.38K
Net Cash Per Share<C$0.01
Tangible Book Value Per Share-C$0.02
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Restart Life Sciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―